INTRODUCTION AND OBJECTIVES: Although widely practiced and broadly recommended for definitive relief of refractory ischemic priapism (RIP), corporoglanular shunts are prone to failure in refractory cases with delayed presentation. We report our updated experience using a novel midshaft penile decompression procedure as a glans sparing alternative to corporoglanular shunts for surgical treatment of RIP.
METHODS: We retrospectively reviewed clinical records for RIP patients treated with penoscrotal decompression (PSD) from 2014 -2018. Priapistic episodes were confirmed as ischemic on the basis of clinical presentation and arterial blood gas abnormalities. All patients had failed irrigations and penile injection of alpha agonist prior to PSD. Patient characteristics, duration and etiology of RIP, prior interventions, and clinical outcomes were recorded.
RESULTS: We analyzed 13 RIP patients (mean age of 29.5 years [range 12 -53]), of which six patients had failed a distal corporoglanular Tshunt prior to PSD and the other seven had failed irrigations and injections only; none had proximal shunts. Despite an extended time to presentation (mean 61.2 hours), all 13 RIP patients had prompt resolution of priapistic symptoms after PSD surgery. The most common priapism etiologies in the cohort were Sickle Cell Disease (4), illicit drug use (4-cocaine, valium, methamphetamine), and intracavernosal injections (3). Other etiologies were depo testosterone and idiopathic. Of the 10 patients with documented follow-up (median 51.5 days), many reported some preservation of potency status after PSD surgery (3-normal erectile function, 2-spontaneous erections, 1-no erections). One with preoperative erectile dysfunction later underwent an inflatable penile prosthesis uneventfully 251 days following PSD.
CONCLUSIONS: Penoscrotal decompression represents a simple and highly effective option for resolution of refractory ischemic priapism. In this challenging population, PSD appears to have a role both in lieu of corporoglanular shunt and as a salvage strategy for those who have failed prior corporoglanular shunts.
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PD44-08 PENILE PROSTHESIS IMPLEMENTATION WHILE ON ANTICOAGULANT THERAPY: A RETROSPECTIVE STUDY
Alfredo Suarez-Sarmiento* Jr., Matthew Brennan, Alfredo Suarez-Sarmiento, Paul Perito, Coral Gables, FL INTRODUCTION AND OBJECTIVES: There are limited studies that look at how a subset of patients undergoing Inflatable Penile Prosthesis (IPP) implantation while on anticoagulant therapy fair postoperatively. IPP is commonly indicated for patients who suffer from atherosclerotic cardiovascular disease (ASCVD), yet some patients cannot temporarily discontinue their anticoagulants for surgery. We sought to evaluate our dual institutional experience to determine factors associated with post-operative outcomes.
METHODS: Patients undergoing IPP implementation while on anticoagulant therapy from 2014 to 2018 were identified from our dual institutional databases. All clinical notes, patient demographics, comorbidities and surgical outcomes were reviewed. Anticoagulant medications were not altered at the time of surgery and patients were given full disclosure of bleeding risk during surgery. For the purpose of this study, patients were followed for post-operative metrics of wound closure, infection, pain and swelling. All patients underwent either penoscrotal or infrapubic placement of IPP with post-operative drains in place.
RESULTS: 110 patients were identified as being on anticoagulant therapy at the time of IPP placement. Our results showed that 108 (98.2%) of our cohort had uncomplicated post-operative courses. We found that these patients did not have excessive infrapubic or scrotal hematoma requiring further drainage or hospitalization. Only 2 patients in our population had an adverse event post-operatively and both patients were on warfarin. Both patients were readmitted and required transfusions without reoperation.
CONCLUSIONS: IPP implantation may be safely completed in the setting of anti-platelet therapy without increased blood loss, hospital stay, or complication rate. With meticulous dissection and closure of corporotomy and the use of a drain for 1-3 days, we observed no increased risk. Informed consent of risk and reward is mandatory, and measures must be taken to ensure that compulsive homeostasis is being performed in this subset of patients. Patients maintained on vitamin K dependent therapies may be better served with bridging. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e823
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